IOL Chemicals Expands Ibuprofen Capacity by 6,000 MT, Adds CDMO Business

IOL Chemicals & Pharmaceuticals Ltd announced significant expansion initiatives. The company is increasing its Ibuprofen manufacturing capacity by 6,000 MT per annum to a total of 18,000 MT, with a ₹350 Crore investment funded by internal accruals. Additionally, it is diversifying into Contract Development and Manufacturing Organisation (CDMO) for pharmaceutical formulations with a new facility costing ₹110 Crore, also funded internally. This new CDMO business, targeting European customers, has received GMP certification and is expected to commercialize in Q3 FY27. The company is also establishing a dedicated specialty chemicals manufacturing facility under a long-term tolling arrangement for a global chemical company, involving a ₹35 Crore investment, expected to commercialize in Q3 FY27.